**Comparing Treatment Approaches for Knee Ligament Laxity and Torn Ligaments: Interventional Orthobiologics Versus Surgical Options – A Regenexx Perspective** Knee...

**Comparing Knee Ligament Laxity and Torn Ligaments: Orthobiologic Interventions vs. Surgical Options – Insights from Regenexx** Knee ligament injuries are...

**Gene Therapy Trial Evaluates Efficacy of Cancer-Targeting Virus in Treating Brain Tumors** In the ever-evolving landscape of cancer treatment, gene...

### 2024 PRP Randomized Controlled Trial Infographic 2.0 by Regenexx: A Comprehensive Overview In the ever-evolving field of regenerative medicine,...

**Comparative Study on the Effectiveness of Stem Cells and Microvesicles in Treating Chronic Renal Injury in Rats: Histological and Biochemical...

**Comparative Analysis of Stem Cells and Microvesicles in Treating Chronic Renal Injury in Rats: A Histological and Biochemical Study –...

**Comparative Study on the Effectiveness of Stem Cells and Microvesicles in Treating Chronic Renal Injury in Rats: A Histological and...

**Jonathan Thomas Appointed as New President and CEO of CIRM** In a significant development for the field of regenerative medicine,...

# $53 Million Allocated for Clinical and Translational Research Funding: A Leap Forward in Medical Innovation In a significant move...

**Correction Notice: Influence of Thyroid Hormone Receptor β on Cancer Stem Cell Activity – Oncogene** In the ever-evolving field of...

**The Role of FOXM1-Dependent Histone Linker H1B in Human Epidermal Stem Cells: Implications for Cell Death and Disease** The human...

**The Role of FOXM1-Dependent Histone Linker H1B in Human Epidermal Stem Cells: Insights from Cell Death & Disease** Human epidermal...

**Nevada Approves Controversial Unproven Therapies, Joining Other States in Challenging FDA Regulations on Biologics** In a move that has sparked...

**QC Kinetix Shifts Focus from Upselling to Cost Reduction – Regenexx Reports** In the ever-evolving landscape of regenerative medicine, QC...

# Effective Approaches for Modeling Aging and Age-Related Diseases Aging is an inevitable biological process that affects all living organisms....

**Infographic on the 2024 PRP Randomized Controlled Trial by Regenexx: A Comprehensive Overview** In the ever-evolving field of regenerative medicine,...

# Semaphorin 3C (Sema3C) Modulates Stromal Microenvironment to Facilitate Hepatocellular Carcinoma Advancement – Insights from Signal Transduction and Targeted Therapy...

**Semaphorin 3C (Sema3C) Modulates Stromal Microenvironment to Facilitate Hepatocellular Carcinoma Progression – Insights from Signal Transduction and Targeted Therapy** Hepatocellular...

**Lung Institute Stem Cell Clinic Ordered to Pay $9 Million in Class Action Lawsuit Settlement** In a landmark decision, the...

# Improvement of Endothelial Function and Reduction of Portal Vein Injury with miRNA-25-3p-Expressing Mesenchymal Stem Cells – Scientific Reports ##...

**Innovative Stem Cell Therapy for Treating Cystic Fibrosis-Related Sinusitis** Cystic fibrosis (CF) is a genetic disorder that primarily affects the...

**Innovative Stem Cell Therapy for Treating Sinusitis in Cystic Fibrosis Patients** Cystic fibrosis (CF) is a genetic disorder that primarily...

**Cytosolic N-terminal Formyl-Methionine Deformylation Promotes Cancer Stem Cell Characteristics and Tumor Progression** Cancer remains one of the most formidable challenges...

**Deformylation of Cytosolic N-terminal Formyl-Methionine Promotes Cancer Stem Cell Characteristics and Tumor Progression – Scientific Reports** Cancer remains one of...

**miR-124-3p Reduces EGR1 Expression to Mitigate Ischemia-Hypoxia Reperfusion Injury in Human iPS Cell-Derived Cardiomyocytes – Scientific Reports** Ischemia-hypoxia reperfusion injury...

**miR-124-3p Suppresses Ischemia-Hypoxia Reperfusion Injury in Human iPS Cell-Derived Cardiomyocytes by Downregulating EGR1 – Scientific Reports** Ischemia-hypoxia reperfusion (IHR) injury...

**Lack of Response from FDA Commissioner Robert Califf on Stem Cell Clinics Raises Concerns** In recent years, the burgeoning field...

# Uniting the Community: Highlights from the 2nd Annual ALSP Conference The 2nd Annual Alternative Legal Service Providers (ALSP) Conference,...

**Uniting the Community at the 2nd Annual ALSP Conference** In an era where legal innovation is rapidly transforming the landscape...

**Pioneering 3D Brain Models Incorporate Cells from Multiple Donors: A Leap Forward in Neuroscience** In the ever-evolving field of neuroscience,...

The Impact of Nudt15 Thiopurine Detoxification Loss on Direct DNA Damage in Hematopoietic Stem Cells – A Study in Scientific Reports

Title: The Impact of Nudt15 Thiopurine Detoxification Loss on Direct DNA Damage in Hematopoietic Stem Cells – A Study in Scientific Reports

Introduction:

Thiopurine drugs, such as azathioprine and mercaptopurine, are widely used in the treatment of various autoimmune and inflammatory diseases, as well as in certain types of cancer. These drugs are metabolized in the body by the enzyme Nudix hydrolase 15 (Nudt15), which plays a crucial role in detoxifying thiopurines. However, recent research has revealed that certain individuals carry genetic variations in the Nudt15 gene, leading to a loss of thiopurine detoxification ability. This genetic variation has been associated with an increased risk of severe adverse drug reactions, including direct DNA damage in hematopoietic stem cells. A study published in Scientific Reports sheds light on the impact of Nudt15 thiopurine detoxification loss on direct DNA damage in hematopoietic stem cells.

Understanding Nudt15 and Thiopurine Metabolism:

Nudt15 is an enzyme that helps in the breakdown of thiopurine drugs into inactive metabolites, preventing their accumulation and potential toxicity. However, certain genetic variations in the Nudt15 gene can result in reduced or complete loss of enzymatic activity. This loss of function leads to impaired detoxification of thiopurines, allowing them to accumulate and cause adverse effects.

The Study:

The study conducted by researchers aimed to investigate the direct DNA damage caused by thiopurines in hematopoietic stem cells with Nudt15 loss-of-function variants. Hematopoietic stem cells are responsible for the production of all blood cells and are crucial for maintaining a healthy immune system.

The researchers used induced pluripotent stem cells (iPSCs) derived from individuals with different Nudt15 genotypes. These iPSCs were then differentiated into hematopoietic stem cells. The cells were exposed to thiopurine drugs, and the researchers assessed the DNA damage using various molecular techniques.

Results:

The study found that hematopoietic stem cells with Nudt15 loss-of-function variants exhibited increased DNA damage when exposed to thiopurine drugs compared to cells with normal Nudt15 function. The DNA damage was observed in the form of DNA double-strand breaks, which are considered highly detrimental to genomic stability.

Furthermore, the researchers discovered that the accumulation of thiopurine metabolites, specifically 6-thioguanine nucleotides (6-TGN), was significantly higher in cells with Nudt15 loss-of-function variants. This suggests that the impaired detoxification ability of Nudt15 leads to increased levels of toxic metabolites, contributing to direct DNA damage.

Implications and Future Directions:

The findings of this study highlight the importance of Nudt15 in protecting hematopoietic stem cells from direct DNA damage caused by thiopurine drugs. Individuals with Nudt15 loss-of-function variants may be at a higher risk of developing severe adverse drug reactions, including bone marrow suppression and myelosuppression.

These findings have significant clinical implications, as they provide a potential explanation for the inter-individual variability in drug response and toxicity observed in patients receiving thiopurine therapy. Identifying patients with Nudt15 loss-of-function variants before initiating thiopurine treatment could help personalize dosing strategies and minimize the risk of adverse reactions.

Further research is needed to explore the underlying mechanisms by which thiopurines induce DNA damage and to develop strategies to mitigate these effects. Additionally, investigating alternative treatment options for individuals with Nudt15 loss-of-function variants may be warranted to minimize the risk of direct DNA damage and improve patient outcomes.

Conclusion:

The study published in Scientific Reports sheds light on the impact of Nudt15 thiopurine detoxification loss on direct DNA damage in hematopoietic stem cells. The findings emphasize the importance of Nudt15 in protecting against thiopurine-induced DNA damage and provide insights into the increased risk of adverse drug reactions associated with Nudt15 loss-of-function variants. This research contributes to our understanding of personalized medicine and highlights the need for further investigation to optimize thiopurine therapy and improve patient safety.